Release Details
Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases
"We are pleased to report strong income from operations of
"We are very encouraged by the strong positive reaction to our recent announcement of a bitcoin treasury strategy," said
FINANCIAL RESULTS
For the second quarter ended
- Revenues of
$14.5 million , a decrease of$4.1 million , or 22%, compared to$18.6 million . - Cost of revenues of
$1.3 million , an increase of$0.1 million , or 3%, compared to$1.2 million - Total operating expenses, which include cost of revenues, of
$9.1 million , a decrease of$2.3 million , or 20%, compared to$11.4 million . - Income from operations of
$5.4 million , a decrease of$1.8 million , or 25%, compared to$7.2 million . - Pre-tax net income of
$1.1 million (which includes the change in fair value on our bitcoin holdings of negative$5.1 million ), a decrease of$6.6 million , or 85%, compared to$7.7 million . - Income tax expense of
$1.1 million , or an effective tax rate of 99%, compared to$1.8 million , or an effective tax rate of 23%. - Net income of
$11 thousand , or breakeven, a decrease of$5.9 million , or 100%, compared to net income of$5.9 million , or$0.88 per basic share and$0.75 per diluted share.
BITCOIN HOLDINGS
On
Subsequently through
Notice of Conference Call
Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10190580/fcfdde76dc. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:
Domestic callers: (833) 816‑1161
International callers: (412) 317‑0717
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on
Semler Scientific, Inc. |
||||||||||||
Condensed Statements of Income |
||||||||||||
Unaudited |
||||||||||||
(In thousands of |
||||||||||||
For the three months ended |
For the six months ended |
|||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||
Revenues |
$ |
14,465 |
$ |
18,605 |
$ |
30,368 |
$ |
36,811 |
||||
Operating expenses: |
||||||||||||
Cost of revenues |
1,255 |
1,219 |
2,501 |
2,488 |
||||||||
Engineering and product development |
1,440 |
1,762 |
2,578 |
3,392 |
||||||||
Sales and marketing |
3,456 |
4,985 |
7,131 |
10,177 |
||||||||
General and administrative |
2,964 |
3,459 |
5,832 |
7,318 |
||||||||
Total operating expenses |
9,115 |
11,425 |
18,042 |
23,375 |
||||||||
Income from operations |
5,350 |
7,180 |
12,326 |
13,436 |
||||||||
Interest and dividend income |
714 |
597 |
1,534 |
1,080 |
||||||||
Change in fair value of notes held for investment |
128 |
(111) |
128 |
(217) |
||||||||
Change in fair value of digital assets |
(5,055) |
— |
(5,055) |
— |
||||||||
Other (expense) income, net |
(4,213) |
486 |
(3,393) |
863 |
||||||||
Pre-tax income |
1,137 |
7,666 |
8,933 |
14,299 |
||||||||
Income tax provision |
1,126 |
1,787 |
2,849 |
3,451 |
||||||||
Net income |
$ |
11 |
$ |
5,879 |
$ |
6,084 |
$ |
10,848 |
||||
Net income per share, basic |
$ |
0.00 |
$ |
0.88 |
$ |
0.88 |
$ |
1.62 |
||||
Weighted average number of shares used in computing basic net |
6,944,664 |
6,707,341 |
6,918,709 |
6,704,306 |
||||||||
Net income per share, diluted |
$ |
0.00 |
$ |
0.75 |
$ |
0.78 |
$ |
1.38 |
||||
Weighted average number of shares used in computing diluted |
7,795,149 |
7,867,001 |
7,789,101 |
7,887,584 |
Semler Scientific, Inc. |
||||||
Condensed Balance Sheets |
||||||
(In thousands of |
||||||
|
|
|||||
2024 |
2023 |
|||||
Unaudited |
||||||
Assets |
||||||
Current Assets: |
||||||
Cash and cash equivalents |
$ |
7,332 |
$ |
57,200 |
||
Restricted cash |
132 |
132 |
||||
Trade accounts receivable, net of allowance for credit losses of |
7,470 |
6,125 |
||||
Short-term notes held for investments |
6,100 |
— |
||||
Inventory, net |
385 |
445 |
||||
Prepaid expenses and other current assets |
2,271 |
2,042 |
||||
Total current assets |
23,690 |
65,944 |
||||
Assets for lease, net |
1,768 |
2,285 |
||||
Property and equipment, net |
620 |
720 |
||||
Long-term investments |
512 |
512 |
||||
Notes held for investment |
— |
5,372 |
||||
Intangible digital assets |
54,945 |
— |
||||
Other non-current assets |
127 |
270 |
||||
Deferred tax assets, net of valuation allowance of |
3,124 |
2,962 |
||||
Total assets |
$ |
84,786 |
$ |
78,065 |
||
Liabilities and Stockholders' Equity |
||||||
Current liabilities: |
||||||
Accounts payable |
$ |
227 |
$ |
402 |
||
Accrued expenses |
5,086 |
4,502 |
||||
Deferred revenue |
840 |
1,120 |
||||
Other short-term liabilities |
211 |
176 |
||||
Total current liabilities |
6,364 |
6,200 |
||||
Long-term liabilities: |
||||||
Other long-term liabilities |
24 |
70 |
||||
Total long-term liabilities |
24 |
70 |
||||
Commitments and contingencies (Note 15) |
||||||
Stockholders' equity: |
||||||
Common stock, |
7 |
7 |
||||
Additional paid-in capital |
12,504 |
11,985 |
||||
Retained earnings |
65,887 |
59,803 |
||||
Total stockholders' equity |
78,398 |
71,795 |
||||
Total liabilities and stockholders' equity |
$ |
84,786 |
$ |
78,065 |
Semler Scientific, Inc. |
||||||
Condensed Statements of Cash Flows |
||||||
Unaudited |
||||||
(In thousands of |
||||||
Six months ended |
||||||
2024 |
2023 |
|||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||
Net income |
$ |
6,084 |
$ |
10,848 |
||
Reconciliation of Net Income to Net Cash Provided by Operating Activities: |
||||||
Depreciation |
346 |
279 |
||||
Deferred tax expense |
(163) |
(207) |
||||
Loss on disposal of assets for lease |
319 |
114 |
||||
Gain on short-term investments |
— |
(237) |
||||
Allowance for credit losses |
(44) |
92 |
||||
Change in fair value of notes held for investment |
(128) |
217 |
||||
Change in fair value of digital assets |
5,055 |
— |
||||
Stock-based compensation |
295 |
860 |
||||
Changes in Operating Assets and Liabilities: |
||||||
Trade accounts receivable |
(1,292) |
(2,240) |
||||
Inventory |
60 |
(7) |
||||
Prepaid expenses and other current assets |
(135) |
(950) |
||||
Other non-current assets |
43 |
106 |
||||
Accounts payable |
(175) |
(326) |
||||
Accrued expenses |
584 |
3,495 |
||||
Other current and non-current liabilities |
(291) |
13 |
||||
Net Cash Provided by Operating Activities |
10,558 |
12,057 |
||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||
Additions to property and equipment |
(48) |
(260) |
||||
Purchase of notes held for investment |
(500) |
(500) |
||||
Purchase of digital assets |
(60,000) |
— |
||||
Proceeds from maturities of short-term investments |
— |
57,707 |
||||
Purchase of short-term investments |
— |
(49,728) |
||||
Purchase of assets for lease |
(674) |
|||||
|
(60,548) |
6,545 |
||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||
Repurchase of warrants |
— |
(1,949) |
||||
Taxes paid related to net settlement of equity awards |
(45) |
(172) |
||||
Stock issuance expenses |
(102) |
— |
||||
Proceeds from exercise of stock options |
269 |
— |
||||
Net Cash Provided by (Used in) Financing Activities |
122 |
(2,121) |
||||
(DECREASE) INCREASE IN CASH |
(49,868) |
16,481 |
||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD |
57,332 |
23,014 |
||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD |
$ |
7,464 |
$ |
39,495 |
Semler Scientific, Inc. |
|||||||||||||||
Digital Assets- Additional Information |
|||||||||||||||
Rollforward of bitcoin holdings |
|||||||||||||||
Unaudited |
|||||||||||||||
Source of |
Digital Assets |
Change in |
Digital Assets |
Approximate |
Approximate |
||||||||||
Balance as of |
$ |
— |
$ |
— |
$ |
— |
— |
$ |
— |
||||||
Digital assets purchased |
(a) |
60,000 |
— |
60,000 |
877 |
68,436 |
|||||||||
Change in fair value of the digital assets |
— |
(5,055) |
(5,055) |
— |
— |
||||||||||
Balance as of |
$ |
60,000 |
$ |
(5,055) |
$ |
54,945 |
877 |
$ |
68,436 |
(a) |
Cash from operations |
About Semler Scientific, Inc.:
Forward-Looking Statements
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "believe," "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding expansion of the healthcare business; seeking a new 510(k) clearance for QuantaFlo with expanded indications for use; purchase of additional bitcoin; value of bitcoin and ability to execute on the bitcoin treasury strategy; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause
No Offer or Solicitation
This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of
INVESTOR CONTACT:
Chief Financial Officer
ir@semlerscientific.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-scientific-reports-second-quarter-2024-financial-results-and-additional-bitcoin-purchases-302214705.html
SOURCE